The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The role of autoSCT in Hodgkin lymphoma
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses the role of autologous stem cell transplantation (autoSCT) in treating patients with Hodgkin lymphoma (HL) who relapse following frontline therapy. It is not yet clear whether non-transplant approaches hold potential for treating this patient population, and therefore, Dr Ansell highlights the need to administer a salvage regimen and proceed to autoSCT for the time being. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
